Development of lipidomic platform to studies and their use in the assessment of response to antipsychotics in patients with schizophrenia

• Grant number: 15/09159-8
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Start date: October 01, 2015
• End date: September 30, 2017
• Field of knowledge: Biological Sciences - Biochemistry
• Principal Investigator: Daniel Martins-de-Souza
• Grantee: Adriano Aquino
• Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Associated research grant: 13/08711-3 - Developing a predictive test for a successful medication response and understanding the molecular bases of schizophrenia through proteomics, AP.JP

Abstract

Schizophrenia is an incurable psychiatric disorder that has a prevalence of 0.5-1% of the world population. Currently, the diagnosis is strictly clinical, based on interviews conducted by psychiatrists, as there are no molecular biomarkers. Biomarkers for prediction of successful treatment are also non-existent, although indispensable due to lack of specificity of treatment for a significant portion of patients. Potential biomarkers of response to treatment can be obtained by lipidomics based on mass spectrometry, a tool that identifies and quantifies large scale and accurately changes in levels of cellular lipids. The combination of techniques such as liquid chromatography (LC) and gas (GC) both coupled to mass spectrometry (MS) has enabled significant advances in the assessment of the lipid profile of various biological matrices. In this context, the project aims to establish a lipidomics analysis platform based on LC-ESI-MS and GC-MS to assist the molecular characterization of schizophrenia. This platform will be used to identify candidates lipid biomarkers present in plasma collected in vivo of patients before and after treatment with antipsychotics quetiapine, olanzapine and risperidone, indicating the medication potential for success. This study will increase the understanding of the molecular basis of schizophrenia and enable the development of a strategy of personalized medicine with potential clinical implementation. Besides, a new lipidomic platform will be implemented for studying and characterizing other brain disorders. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

AQUINO, ADRIANO; ALEXANDRINO, GUILHERME L.; GUEST, PAUL C.; AUGUSTO, FABIO; GOMES, ALEXANDRE F.; MURGU, MICHAEL; STEINER, JOHANN; MARTINS-DE-SOUZA, DANIEL. Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. FRONTIERS IN PSYCHIATRY, v. 9, MAY 25 2018. (17/25588-1, 15/08201-0, 15/09159-8, 13/08711-3, 14/10068-4)

DE ALMEIDA, VALERIA; ALEXANDRINO, GUILHERME L.; AQUINO, ADRIANO; GOMES, ALEXANDRE F.; MURGU, MICHAEL; DOBROWOLNY, HENRIK; GUEST, PAUL C.; STEINER, JOHANN; MARTINS-DE-SOUZA, DANIEL. Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v. 101, JUL 13 2020. (17/25588-1, 15/08201-0, 14/10068-4, 17/18242-1, 15/09159-8, 19/00098-7)